Related Experiment Video
Updated: May 16, 2025

Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
Accounting for Hypoglycemia Treatments in Continuous Glucose Metrics
Elliott C Pryor1, Anas El Fathi1, Marc D Breton1
1Center for Diabetes Technology, University of Virginia, Charlottesville, VA, USA.
Insights
Continuous glucose monitoring (CGM) data can be improved by accounting for hypoglycemia treatments (HTs). New methods accurately quantify avoided hypoglycemia, enhancing diabetes management and treatment adaptation for better blood glucose control.
Area of Science:
- Biomedical Engineering
- Data Science in Healthcare
- Endocrinology
Background:
- Continuous glucose monitoring (CGM) provides valuable diabetes data but omits behavioral factors like hypoglycemia treatments (HTs).
- Hypoglycemia treatments mask actual glucose exposure, potentially leading to management errors.
- Accurate assessment of hypoglycemia requires integrating behavioral data with CGM metrics.
Purpose of the Study:
- To develop a method for incorporating HTs into CGM-based metrics.
- To standardize the quantification of hypoglycemia exposure considering treatment proactiveness and severity.
- To introduce an HT detector for identifying undocumented HTs in CGM data.
Main Methods:
- Proposed a novel method to integrate HTs into CGM metrics for standardized hypoglycemia quantification.
- Developed an HT detector to identify treatment instances within CGM data.
- Applied HT-modified hypoglycemia metrics to a run-to-run treatment adaptation system.
Main Results:
- Reconstructed avoided hypoglycemia exposure with high fidelity (R² = .94) using in-silico data.
- Achieved an F1 score of 0.72 for the HT detector on clinical data.
- Reduced average daily HTs from 3.3 to 1.6 in a run-to-run system while maintaining 84% time in range.
Conclusions:
- The new metric integrates HT behaviors into CGM analysis for behavior-sensitive hypoglycemia assessment.
- This approach enhances Type 1 Diabetes (T1D) management by providing more robust treatment insights.
- HT variability can be seamlessly incorporated into existing CGM methods for improved diabetes care.
Background:
Continuous glucose monitoring (CGM) is increasingly used in the management of diabetes, providing dense data for patients and clinical providers to review and identify patterns and trends in blood glucose. However, behavioral factors like hypoglycemia treatments (HTs) are not captured in CGM data. Hypoglycemia treatments, by definition, reduce the visibility (frequency and duration) of hypoglycemia exposure recorded by CGM, which can lead to errors in treatment management when relying solely on CGM metrics.
Methods:
We propose a method to incorporate HTs into CGM-based metrics and standardize hypoglycemia exposure quantification for a variety of HT behaviors; specifically (1) treatment proactiveness and (2) potential severity of the avoided hypoglycemia. In addition, we introduce an HT detector to identify instances of HT using in CGM data that otherwise lack HT documentation. We then use the HT-modified hypoglycemia metrics in a previously published run-to-run treatment adaptation system using CGM-based metrics.
Results:
Using in-silico data to correct time-below-range with HT, we reconstruct the avoided hypoglycemia exposure with high fidelity (R2 = .94). Our HT detector has an F1 score of 0.72 on clinical data with labeled HT. In the example run-to-run application, we reduce the average number of HT per day from 3.3 in the HT-unaware system to 1.6, while maintaining 84% time in 70 to 180 mg/dL.
Conclusion:
This new metric integrates HT behaviors into CGM-based analysis, offering a behavior-sensitive measure of hypoglycemia exposure for more robust T1D management. Our results show that HT can be seamlessly incorporated into existing CGM methods, enhancing treatment insights by accounting for HT variability.
More Related Videos
Related Concept Videos
Hypoglycemia and Glucagon
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
SBAR II: Application of SBAR
SBAR Report from a Nurse to a Health Care Provider
S: "Hello, Dr. Smith. This is Jane, RN, from the Med Surg unit. I am calling to tell you about Ms. White in Room 210, who is experiencing increased pain and redness at her incision site. Her recent...
Oral Hypoglycemic Agents: Glinides
Diabetes Mellitus: Type 2 and Gestational
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are...

